Effect of a new class of compounds of the group of substituted 5R1, 6H2-1,3,4-thiadiazine-2-amines on the inflammatory and cytokine response in experimental myocardial infarction.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Bentham Science Publishers Country of Publication: United Arab Emirates NLM ID: 101157208 Publication Model: Print Cited Medium: Internet ISSN: 1875-6212 (Electronic) Linking ISSN: 15701611 NLM ISO Abbreviation: Curr Vasc Pharmacol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Sharjah, U.A.E. ; San Francisco, CA : Bentham Science Publishers, c2003-
    • Subject Terms:
    • Abstract:
      This study investigated the effects of the L-17 compound of the group of substituted 5R1, 6H2- 1,3,4-thiadiazine-2-amines on the immune response and the plasma level of circulating cytokines in acute myocardial infarction (MI) in rats. The study was based upon experimental work which demonstrated the role of local and systemic inflammatory reactions in MI. Acute MI in rats was induced by left coronary artery coagulation. Histological study of the myocardium sections has been carried out at the 1(th) and 7(th) days of the experimental myocardial infarction. Serum activity of creatine phosphokinase (CPK), aspartate aminotransferase (AST), isoenzymes 1 and 2 and lactate dehydroge nase (LDH1-2) were investigated at days 1(st)and 7(th). ELISA analysis for plasma cytokine levels was performed using commercially available test kits following the manufacturer's instructions. Biochemical analysis in animals with the administration of the L-17 compound after MI showed that the AST and CPK levels at days 5 and 7 of experiments did not differ significantly from the values of intact animals. In animals of the group with MI without the administration of the L-17 compound, the IL-1 level 8 times and the TNF level 7.8 times exceeded the normal indicators, while the use of L-17 compound in the therapy resulted in only 1.8 times increase of IL-1 level and 4.7 times increase of TNF level in comparison with the norm. Thus, the introduction of L-17 compound in case of experimental MI delays exudative/alternative phase of inflammation, accelerates granulocytic and decreased the inflammation and anti-inflammation interleukins level.
    • Accession Number:
      0 (Amines)
      0 (Interleukin-1)
      0 (Thiadiazines)
      0 (Tumor Necrosis Factor-alpha)
      EC 1.1.1.27 (L-Lactate Dehydrogenase)
      EC 2.6.1.1 (Aspartate Aminotransferases)
      EC 2.7.3.2 (Creatine Kinase)
    • Publication Date:
      Date Created: 20130501 Date Completed: 20151130 Latest Revision: 20191027
    • Publication Date:
      20240829
    • Accession Number:
      10.2174/15701611113119990005
    • Accession Number:
      23628009